Pentravan | 2019 Transdermal delivery of Metformin Hydrochloride from a semisolid vehicle Polonini HC, Lopes CPJ, Andrade Junquiera L, Loures S, Raposo NRB, Brandao MAF, Ferreira AO International Journal of Pharmaceutical Compounding, 23(1), 65-69 The use of Pentravan to deliver metformin hydrochloride through the skin was evaluated. A 46.7% permeation percentage was found, with a drug flux of 3.91 µg cm/-2/h-1 and a lag time of 0.51 h, suggesting the transdermal route can be an option for patients searching for diverse clinical effects. Read more SEE PRODUCT
Pentravan | 2019 Transdermal Desmopressin as an alternative dosage form for the treatment of nocturia Junqueira LA, Bezerra AA jr, Lopes Candido PJ, Polonini HC, Ferreira AO, Raposo NRB, Brandao MAF Journal of Multidisciplinary Engineering Science and Technology, 6 (10), 888-892 The main objective of the study was to evaluate the ex vivo permeation of a transdermal formulation containing desmopressin, using Pentravan®. The formulation developed was able to promote transdermal absorption of desmopressin, showing a permeation percentage of 21.5%. Thus, sufficient amounts of desmopressin were delivered to achieve a systemic effect. Read more SEE PRODUCT
Pentravan | 2019 Activators of SIRT1 in wound repair: An animal model study Christovam AC, Theodoro V, Sampaio Mendoça FA, Marretto Esquisatto MA, Tech dos Santos GM, Corezola do Amaral ME Archives of Dermatological Research, 311(3), 193-201 The study aimed to study the effect of caloric restriction (CR) and resveratrol (Rv) in wound repair. Results show that the CR and Rv group had enhanced numbers of blood vessels, VEGF, fibroblast, birefringent collagen fiber areas in the lesion and may modulate angiogenesis, fibroplasia, and collagenesis. Read more SEE PRODUCT
Pentravan | 2019 Permeation efficacy of a transdermal vehicle with steroidal hormones and nonsteroidal anti-inflammatory agents as model drugs Junqueira LA, Polonini HC, Loures S, Raposo NRB, Ferreira AO, Brandao MAF Current Drug Delivery, 16(2), 136-141 In this study, a new transdermal vehicle was evaluated using progesterone, estradiol, estradiol + estriol (Biest) and ketoprofen administered as model drugs. For all drugs, sufficient amounts were delivered to achieve a systemic effect, and it was also possible to decrease the amount of emulsion applied. Read more SEE PRODUCT
TrichoConcept | 2019 Effects of Trichosol™ on increasing the anagen phase of the capillary cycle of volunteers Velasco PA, Oliveira A, Amaral F, Rocha Oliveira C Journal of Cosmetology and Trichology, 5(1), 139 This study aimed to investigate the potential of Trichosol™, associated with Minoxidil (3%), in the promotion of hair growth. The results indicated that after treatment for 90 days with the combination of Minoxidil (3%) and Trichosol™, both sexes presented increase in the percentage of anagen phase. Read more SEE PRODUCT
Pentravan | 2019 The complexation of steroid hormones into cyclodextrin alters the toxic effects on the biological parameters of Zebrafish (Danio rerio) Galvao da Silva MC, Freitas da Silva J, Pinheiro Santos T, Correia da Silva NP, Rodrigues dos Santos A, Correa de Andrade AL, Lima da Silva Souza EH, Ribeiro Sales Cadena M, Bezerra de Sa F, Amaro da Silva V jr, Gonçalves Cadena P Chemosphere, 214, 330-340 This study aimed to evaluate the toxicity of progesterone (P4F) and estradiol (E2F) and their effect complexed into cyclodextrins, and evaluate them as endocrine disruptors through biological parameters of Danio rerio. According to these results, there is a higher toxicity effect of hormones in the free form. Read more SEE PRODUCT
Pentravan | 2018 Feasibility study evaluating Pentravan® for the intravaginal administration of active pharmaceutical ingredients to reduce pelvic pain related to endometriosis Polonini HC, Loures S, Alves MC, Ferreira AO, Brandao MAF, Raposo NRB Drug Delivery Letters, 8(3), 200-208 This study aimed to evaluate the preliminary feasibility of using Pentravan® to compound dienogest, gestrinone, nimesulide and piroxicam and their vaginal administration to patients with pelvic pain associated with endometriosis (PPRE). Pentravan® seems to be a feasible intravaginal vehicle, particularly for delivery of dienogest and gestrinone for for PPRE treatment. Read more SEE PRODUCT
OrPhyllo | 2018 Compounded Orodispersible Films with natural ingredients for halitosis: A clinical experience Apolinario RDS, Chaves MDG, Afonso M, Gonçalves HRM, Martins ICF, De Paula RM, Granato APA, Polonini HC, Brandao MAF, Ferreira AO, Raposo NRB International Journal of Pharmaceutical Compounding, 22(6), 512-515 The study aimed to evaluate the therapeutic effect of two natural extracts, Camellia sinensis (green tea) and resveratrol in the form of oral polymer films, to control halitosis. Results showed a statistically significant reduction in volatile sulfur compound levels in 71.79% of the volunteers. Read more
SiliciuMax | 2018 Anti-aging effects of Monomethylsilanetriol and Maltodextrin-Stabilized Orthosilicic Acid on nails, skin and hair Ferreira AO, Santos Freire E, Polonini HC, Lopes Candido da Silva PJ, Brandao MAF, Raposo NRB Cosmetics, 5(3), 41-56 This study investigated the dermatological effects of oral ingestion of SiliciuMax, either solid or liquid, on the skin, hair and nails of healthy volunteers. Use of SiliciuMax provided significant betterment of wrinkles and UV spots. Changes were also observed in skin texture and eyelash length. Hair aluminium levels decreased. Read more
Pinetonina | 2018 Pinetonina, an intranasally administered Essential Oil preparation, is effective in decrease of cortisol levels and on the Glutamate release modulation Jardin M, Amaral F, de Souza Antunes VM, Rodrigues F, Soares Alves de Souza M, Rossi Siqueto F, Silva LM, Alves Bertolino R, Cavalaro V, Rocha Oliveira C Neuroscience & Medicine, 9(3), 135-149 A reduction in dose-dependent cell viability was observed in treated fibroblasts. When Pinetonin and linole are administered in astrocytic cells, there was a reduction of the intracellular concentration of Ca2+ against a control group treated with DHPG agonist. The evaluation of salivary cortisol demonstrated a reduction in the treated group. Read more